Unicycive Therapeutics (NASDAQ:UNCY) Raised to “Hold” at Wall Street Zen

Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities research analysts have also recently issued research reports about the company. Benchmark upped their price target on Unicycive Therapeutics to $21.00 and gave the stock a “speculative buy” rating in a report on Monday, September 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.00.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $4.44 on Friday. Unicycive Therapeutics has a fifty-two week low of $3.53 and a fifty-two week high of $11.00. The company has a market capitalization of $78.41 million, a price-to-earnings ratio of -1.08 and a beta of 1.86. The firm has a 50-day simple moving average of $4.24 and a 200-day simple moving average of $5.23.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.18. Equities research analysts forecast that Unicycive Therapeutics will post -0.23 EPS for the current year.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of hedge funds have recently made changes to their positions in UNCY. Vivo Capital LLC lifted its holdings in Unicycive Therapeutics by 14.0% in the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock worth $6,537,000 after buying an additional 1,400,000 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics in the 2nd quarter worth $55,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.